Martin Christopher Nathan 4

What Happened

• Martin Christopher Nathan, a director of Achieve Life Sciences, received an award/option grant for 47,250 shares on May 11, 2026. The reported acquisition price is $0.00 (derivative award), so no cash changed hands at grant. This is an equity compensation award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-11; filing date: 2026-05-13 (timely filing).
• Award: 47,250 shares; reported price: $0.00; transaction code: A (award/grant).
• Vesting: The option will vest in substantially equal monthly installments over 36 months commencing May 11, 2026, subject to continued service (per footnote).
• Shares owned after the transaction: not specified in this Form 4.
• This is a derivative/option grant (not an immediate sale or purchase of market shares).

Context

• This grant is a typical form of executive/director compensation intended to align long-term interests; because it vests over three years, the shares are not immediately available for sale and require continued service (and likely exercise) before becoming marketable. The grant itself does not represent a market buy or sell and does not provide immediate cash value.